The stock of Knight Therapeutics Inc (TSE:GUD) hit a new 52-week high and has $10.99 target or 7.00% above today’s $10.27 share price. The 5 months bullish chart indicates low risk for the $1.39 billion company. The 1-year high was reported on Nov, 25 by Barchart.com. If the $10.99 price target is reached, the company will be worth $97.30 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 14,023 shares traded hands. Knight Therapeutics Inc (TSE:GUD) has risen 26.66% since April 21, 2016 and is uptrending. It has outperformed by 21.25% the S&P500.
Knight Therapeutics Inc (TSE:GUD) Ratings Coverage
Out of 2 analysts covering Knight Therapeutics (TSE:GUD), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $11 is the highest target while $9.50 is the lowest. The $10.27 average target is 0.00% above today’s ($10.27) stock price. Knight Therapeutics has been the topic of 5 analyst reports since May 12, 2016 according to StockzIntelligence Inc.
More important recent Knight Therapeutics Inc (TSE:GUD) news were published by: Reuters.com which released: “Exclusive: Endo considers sale of Paladin Labs to Knight Therapeutics – so…” on November 04, 2016, also Seekingalpha.com published article titled: “How Many Times Can Knight Therapeutics Issue Equity?”, Seekingalpha.com published: “Put Knight Therapeutics On Your Watchlist” on April 01, 2016. More interesting news about Knight Therapeutics Inc (TSE:GUD) was released by: Prnewswire.com and their article: “Braeburn Pharmaceuticals and Knight Therapeutics Announce Canadian Sublicense …” with publication date: February 01, 2016.
Knight Therapeutics Inc is a Canada pharmaceutical company. The company has a market cap of $1.39 billion. The Firm is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It has a 73.37 P/E ratio. It finances other life sciences companies in Canada and internationally.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.